Drugs / Autologous Immune Killer Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03592706 | Dec 2009 → Feb 2021 | hepatocellular carcinoma | Ivy Life Sciences, Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Immune Killer Cells | “Autologous Immune Killer Cells” NCT03592706 ↗ |
| Known as | IKC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03592706 ↗ |